Onco-dermatology and therapies
Posted by
fsena
on 10 July 2020
Efficient Therapeutic Delivery by a Novel Cell-Penetrating Peptide Derived from Acinus
Habault J, Fraser C, Pasquereau-Kotula E, Born-Bony M, Marie-Cardine A, Poyet JL Nature: Cancers (Basel). [...]
Read morePosted by
aline
on 1 July 2020
Immunity to commensal skin fungi promotes psoriasiform skin inflammation
Charlotte Hurabielle, Verena M. Linka, Nicolas Bouladouxa, Seong-Ji Hana, Eric Dean Merrilla, Yaima L. [...]
Read morePosted by
fsena
on 16 May 2020
Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease
Talvard-Balland N, Sutra Del Galy A, Michonneau D, Le Buanec H, Chasset F, Robin M, Peffault de Latour R, [...]
Read morePosted by
fsena
on 14 May 2020
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas
Dangien A, Ram-Wolff C, Brice P, Battistella M, Roelens M, Moins-Teisserenc H, Peffault de Latour R, Mourah [...]
Read morePosted by
fsena
on 25 April 2020
FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma
Tétu P, Delyon J, André J, Reger de Moura C, Sabbah M, Ghanem GE, Battistella M, Mourah S, Lebbé C, Dumaz N [...]
Read morePosted by
fsena
on 2 March 2020
Prophylactic and therapeutic antileukemic effects induced by the AAC-11-derived Peptide RT53
Habault J, Kaci A, Pasquereau-Kotula E, Fraser C, Chomienne C, Dombret H, Braun T, Pla M, Poyet JL Nature: [...]
Read morePosted by
fsena
on 16 November 2019
CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker
Landras A, Reger de Moura C, Jouenne F, Lebbe C, Menashi S, Mourah S Nature: Cancers (Basel). 2019 Nov [...]
Read morePosted by
fsena
on 30 August 2019
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff [...]
Read morePosted by
fsena
on 18 August 2019
Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
Louveau B, Jouenne F, Reger de Moura C, Sadoux A, Baroudjian B, Delyon J, Herms F, De Masson A, Da Meda L, [...]
Read morePosted by
fsena
on 8 August 2019
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
Dumaz N, Jouenne F, Delyon J, Mourah S, Bensussan A, Lebbé C Nature: Cancers (Basel). 2019 Aug 8;11(8):1133 [...]
Read more